RVL Pharmaceuticals PLC Sustainability Reports
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the development and commercialization of ophthalmic products. Its primary commercial product is Upneeq, an FDA-approved prescription eye drop for the treatment of acquired blepharoptosis (low-lying eyelids) in adults.
Sector: Manufacturing
Country: United States
Exchange: OTC Markets
LEI: 549300UFONE2USNRQ615
FIGI: BBG00LZQJQM5
1 reports from 2022 to 2022